Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker

Figure 9

GSEA in the high GINS2 group and low GINS2 group. (a) Enrichment analysis of KEGG pathway in the high GINS2 expression group. (b) Enrichment analysis of KEGG pathway in the low GINS2 expression group. (c) Pathway analysis of HALLMARK by the high GINS2 group. (d) Enrichment in HALLMARK by samples with low GINS2 expression.

(a)

(b)

(c)

(d)